AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating ...

AbbVie has won expanded European approval of its blockbuster autoimmune drug Rinvoq for the treatment of adults with giant cell arteritis.

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...

Rinvoq (upadacitinib) is a prescription drug that works to treat certain inflammatory conditions by decreasing the activity of immune system cells. Your response to this drug may vary based on ...

Certain factors, such as the form of Rinvoq you’re prescribed, may determine whether you should take the drug during this time. If you may be or can become pregnant, it’s important to consider ...

A second stage of the study, which has yet to generate results, is looking at whether patients who achieve remission with Rinvoq can maintain that status while the drug is phased out. Rinvoq is a ...

Routinely monitor liver enzymes; interrupt therapy if ALT/AST elevated and drug-induced liver injury is suspected. Monitor lipids 12 weeks following initiation and manage hyperlipidemia.

The company needs Rinvoq and another new immunology drug – recently-approved psoriasis therapy Skyrizi (risankizumab) – to help offset the expected declines in Humira sales once biosimilar ...

AbbVie’s Skyrizi and Rinvoq were practically unshakeable atop the monthly TV drug ad spending rankings, ultimately leading ...

In this wide and deep sector, though, there are some notable exceptions. Let's take a look at two outliers with dividend policies that have looked especially attractive lately -- pharmaceutical ...

The medication, Rinvoq, is approved for use in children as young as 2 years old, but for Milana Scaccio’s condition, the medical labeling indicates it’s for patients aged 18 and older.

AbbVie's fourth-quarter revenue exceeded forecasts on higher sales of its Skyrizi and Rinvoq drugs to treat inflammation. The demand for those two treatments offset continuing falling sales of its ...